NCT04737928

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Santen Pharmaceutical (Taiwan) Co., LTD · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study was to investigate the improving effect of corneal disorder in primary open-angle glaucoma and ocular hypertension patients, when switched from the 0.005% latanoprost ophthalmic solution (one drop at a time, once daily) to the 0.0015% tafluprost ophthalmic solution (one drop at a time, once daily). Efficacy also was investigated.

Conditions

• Glaucoma, Primary Open Angle

Interventions

Type	Name	Description
DRUG	Latanoprost	latanoprost 0.05%(one drop, once daily)
DRUG	tafluprost	tafluprost 0.015% (one drop, once daily)

Timeline

• Start date: 2018-04-02
• Primary completion: 2019-01-22
• Completion: 2019-01-22
• First posted: 2021-02-04
• Last updated: 2021-02-04

Locations

1 site across 1 country: Taiwan